hit identification

Views & Analysis

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

News

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.